Stockwinners Market Radar for March 16, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:16 EDT Charles Schwab director buys $233.5K in common stock - In a regulatory filing, Charles Schwab disclosed that its director Mark Goldfarb bought 4.0K shares of common stock on March 16th in a total transaction size of $233.5K.

19:48 EDT American Homes 4 Rent CFO sells $1.1M in common stock - In a regulatory filing, American Homes 4 Rent disclosed that its CFO Christopher Lau sold 36.2K shares of common stock on March 14th in a total transaction size of $1.1M.

19:34 EDT Astellas Pharma / Pfizer announce positive results from Embark trial of XTANDI - Pfizer (PFE) and Astellas Pharma (ALPMY) "announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. Patients enrolled in the trial were randomized to one of three study arms: XTANDI plus leuprolide, placebo plus leuprolide, or XTANDI monotherapy. The study met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival for patients treated with XTANDI plus leuprolide versus placebo plus leuprolide. At the time of the analysis, a positive trend in the key secondary endpoint of overall survival (OS) was also observed, but these data were not yet mature. Patients in the trial will be followed for a subsequent final OS analysis. The study also met a key secondary endpoint with a statistically significant and clinically meaningful improvement in MFS for patients treated with XTANDI monotherapy versus placebo plus leuprolide. Additional key secondary endpoints reached statistical significance, including time to prostate-specific antigen progression and time to first use of new antineoplastic therapy. Other secondary endpoints are being analyzed. No new safety signals have been observed to date in the preliminary safety analysis, which is consistent with the established safety profile of XTANDI."

18:55 EDT KeyCorp CFO Donald Kimble to retire - On March 16, 2023, in connection with his previously announced retirement, Donald R. Kimble retired from his position as CFO of KeyCorp. The Company's Board of Directors appointed Clark H. I. Khayat as Chief Financial Officer effective that same day. Mr. Kimble will remain as Vice Chairman and Chief Administrative Officer of the Company until May 1, 2023, to facilitate the transition of his duties.

18:45 EDT Signet Jewelers CEO: Our financial health is very strong - In an interview on CNBC's Mad Money, Virginia Drosos said Signet's financial health allows it to invest in its competitive advantages. Its liquidity is three times higher than when it started its transformation, she noted.

18:31 EDT Okta CEO: The fundamentals of our business are very sound - In an interview on CNBC's Mad Money, Todd McKinnon said workforce identity is 60% of the company's revenue with customer identity representing 40%. The goal is to get to an even split. "There is leverage in our business model," he noted.

18:23 EDT Okta CEO: The fundamentals of our business are very sound - In an interview on CNBC's Mad Money, Todd McKinnon said workforce identity is 60% of the company's revenue with customer identity representing 40%. The goal is to get to an even split. There is leverage in our business model, he noted.

18:04 EDT Enzo Biochem jumps 121% to $2.63 after selling Clinical Laboratory to Labcorp

17:59 EDT Nexa Resources says production at Cerro Lindo mine suspended - Nexa Resources informs that production at the Cerro Lindo mine is suspended due to unusual heavy rainfall levels and overflowing rivers caused by Cyclone Yaku, which has been affecting the region, as well as other parts of the country. Nexa's underground mine received more water than it could pump to the surface, partially flooding some lower levels of the mine. Road access was also compromised. Nexa is closely monitoring and evaluating the situation as it develops and is taking all necessary precautions to ensure the safety of its employees, contractors and host communities. On a daily basis, Cerro Lindo produces approximately 233t of zinc. Production has not yet been impacted month to date. "We expect to be able to resume production within the next ten to twelve days, subject to the dewatering process in the underground mine and the impact of rainfall on other areas of the operation. The potential impact on the 2023 guidance and its results are under review. Nexa reiterates its commitment to the health and safety of its employees and will keep the market informed of further developments."

17:54 EDT Airbnb director sells $41.0M in common stock - In a regulatory filing, Airbnb disclosed that its director Joseph Gebbia sold 350K shares of common stock on March 14th for $41.0M.

17:40 EDT Lockheed Martin awarded $143.09M Navy contract modification - Lockheed Martin was awarded a $143.09M cost-plus-incentive-fee contract modification to previously awarded contract to exercise options for Navy equipment and spares. Work is expected to be completed by February 2031. FY23 other procurement funds in the amount of $81.35M; FY23 shipbuilding and conversion funds in the amount of $59,48M and FY22 shipbuilding and conversion funds in the amount of $2,253,093 will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:20 EDT Lowe's exec Frieson sells 9,411 common shares - In a regulatory filing, Lowe's executive VP, supply chain, Donald Frieson disclosed the sale of 9,411 common shares of the company on March 15 at a price of $197 per share.

17:16 EDT Coinbase investigating elevated error rates, says funds are safe - Coinbase said in a tweet that it is currently investigating elevated error rates across coinbase.com on both web and mobile. Customers may have trouble trading or selecting assets to withdraw. "Rest assured funds are safe and we're working to fix ASAP," the company said. "We'll update you here shortly." Reference Link

17:14 EDT Diebold down 9%, sees risk to generating cash to sustain operating needs - In its 10-K filing's Strategic and Operational Risks statement, Diebold says: "The Company may not be able to generate sufficient cash from operations or have access to other sources of liquidity to sustain its operating needs or to meet its obligations as they become due over the next twelve-month period, raising substantial doubt as to the Company's ability to continue as a going concern. The Company may not be able to generate sufficient cash from operations or have access to other sources of liquidity to sustain its operating needs or to meet its obligations as they become due over the next twelve-month period, raising substantial doubt as to the Company's ability to continue as a going concern. As discussed below under "-Risks Related to Our Indebtedness," the Company has substantial indebtedness and requires sufficient cash flows and capital resources to fund its debt service obligations and other liquidity needs. Although the Refinancing Transactions completed in December 2022 were intended to provide the Company with the necessary liquidity to meet, along with cash from operations, its near-term and long-term liquidity needs, the available borrowing capacity under the ABL Facility has been substantially limited due to a lower than expected borrowing base. In addition, slower-than-expected conversion of inventory into revenue has further suppressed liquidity. As a result, without modifications to the ABL Facility and access to additional capital, the Company currently projects that it will have insufficient liquidity to satisfy its obligations as they become due over the next twelve-month period. The Company has been in discussions with certain of its lenders regarding various liquidity solutions, including a short-term "first-in-last-out" facility to be provided under its ABL Facility, which a lender has provided a "highly confident letter" for, subject to customary conditions. The Company expects the first-in-last-out facility to provide $55.0 of additional liquidity and to close by March 20, 2023, however, there can be no assurance that such a facility will be entered into by such date or at all. In addition, the Company is in discussions with its lenders about other strategic initiatives and liquidity solutions for its business." Shares of Diebold are down 8.7% afterhours at $2.10.

17:03 EDT U.S. Steel jumps over 4% to $25.61 after positive Q1 pre-announcement

17:03 EDT Alcoa to close Intalco smelter - Alcoa "announced the closure of its Intalco aluminum smelter in Washington State, which has been fully idle since 2020. The closure announcement begins a process to prepare the site for new economic development opportunities. Pursuant to an agreement with AltaGas (TSX: ALA), AltaGas has acquired the rights to develop and own approximately 1,600 acres at the Intalco site, which includes transportation and utility infrastructure. Permanently closing Intalco's 279,000 metric tons of annual capacity will bring Alcoa Corporation's global consolidated capacity to 2.69 million metric tons, including a combined 399,000 metric tons at two other smelters in the United States. Alcoa will record restructuring and related charges in the first quarter 2023 of approximately $120 million, or $0.67 per share, related to the permanent closure. Cash outlays related to the permanent closure of the site are expected to be approximately $85 million over the next three years, with approximately $25 million to be spent in 2023. The Intalco smelter was fully curtailed in the third quarter of 2020, amid declining market conditions and high input costs. The smelter, which began operation in 1966, lacks access to competitively priced power and would have required significant capital expenditures to restart."

16:56 EDT Steven Madden CEO sells $1.99M in common stock - In a regulatory filing, Steven Madden disclosed that its CEO Edward Rosenfeld sold 58K shares of common stock on March 15th in a total transaction size of $1.99M.

16:53 EDT Groupon expects to reduce current cost structure by an additional $100M - "We have significantly reduced our cost structure; we've lowered our full-year GAAP SG&A expenses by over $320 million compared with 2019 levels, or $240 million on a non-GAAP basis. We continue to execute on our multi-phase restructuring plan to ensure that our cost structure remains aligned with where our business is today while providing us with room to grow. Our phase 1 cost actions, which were substantially complete in 2022, removed $150 million of annualized costs from our business. We have expanded and accelerated the second phase of our restructuring plan and now expect to reduce our current cost structure by an additional $100 million, which is twice the size of our original plan. We expect to hit this annualized savings run-rate by the end of 2023 by executing on the following initiatives: Reducing our annualized payroll costs by eliminating approximately 500 positions globally, with the majority of these reductions expected to occur by the end of the second quarter of 2023, and to a lesser extent, implementing other non-payroll actions, including reducing technology, software and certain professional services costs, to create an additional $30 million in annualized cost savings. We expect to realize the majority of savings related to our phase 1 and 2 cost actions by the end of 2023. Based on this, we estimate that our 2023 non-GAAP SG&A expense will be more than $350 million lower than 2019 levels. Our non-GAAP SG&A expense excludes stock-based compensation and depreciation and amortization. Notwithstanding the progress that has been made, the Board is disappointed in the company's results for the fourth quarter and 2022 and plans to continue to assess the factors contributing to such results. The Board remains committed to the successful transformation of Groupon and the creation of value of our stockholders."

16:51 EDT Groupon withdraws previous FY23 free cash flow, adjusted EBITDA margin guidance - Cites execution of turnaround strategy, combined with an uncertain macroeconomic environment.

16:44 EDT SoFi Technologies CEO Noto buys $243K in company shares - The CEO of SoFi Technologies Anthony Noto disclosed in a filing that he had purchased 45,000 shares of company stock for $5.39 per share on March 16, for a total transaction amount of $242,712.

16:38 EDT Jounce: Patients from ovarian cancer combo cohort study had durable responses - Jounce Therapeutics announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review. The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors. JTX-8064, is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage receptor Leukocyte Immunoglobulin Like Receptor B2 , inhibiting LILRB2 binding with its ligands which may result in reprogramming immune-suppressive macrophages to enhance anti-tumor immunity. "Tumor reduction was observed at 9 weeks in all the responding patients in the ovarian cancer cohort of the INNATE trial, but most did not achieve a PR until week 18, which delayed our ability to assess efficacy in this cohort. Platinum resistant ovarian cancer is a patient population with significant unmet need and progressive disease is often associated with debilitating symptoms." Enrollment has been completed in all cohorts in the INNATE trial. In addition to the patients with ovarian cancer, both durable responses and stable disease have occurred in patients with renal cell carcinoma, biliary tract cancer, and first-line and second/third-line head and neck squamous cell carcinoma, but the ovarian data is the most encouraging with potential to achieve pre-determined POC criteria. As previously announced, Jounce is seeking to partner JTX-8064. Jounce continues to believe a company with additional resources and a longer value creation timeline could potentially advance this program for the benefit of cancer patients.

16:34 EDT Enzo Biochem to sell Clinical Laboratory division to Labcorp, terms undisclosed - Enzo Biochem (ENZ) announced that it has entered into an agreement for Labcorp (LH) to acquire the assets of Enzo's Clinical Laboratory division. The transaction between two global life sciences companies follows several steps initiated by Enzo in 2022 to advance the company's "focused return" initiative. In 2022, Enzo Biochem initiated a strategic initiative to restructure operations to target business areas and industry sectors. The company's remaining operating segment, Enzo Life Sciences, supplies a portfolio of products and services that are used in drug discovery, development and translational research applications. Enzo Life Sciences' products including antibodies, genomic probes, assays, biochemicals, and proteins are sold globally to the life sciences market. Completion of the sale of Enzo Clinical Labs is contingent upon approval by Enzo's shareholders and other customary closing conditions for transactions of this type, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Other terms of the transaction will be disclosed in the company's Form 8-K to be filed with the Securities and Exchange Commission. Enzo plans to seek shareholder approval of the proposed sale at a special meeting of shareholders. More complete information regarding the transaction will be provided to Enzo's shareholders in materials to be distributed for the special meeting.

16:31 EDT Nikola says battery manufacturing move to Arizona ahead of schedule - Nikola announced that the move to transition battery manufacturing from Cypress, Calif. to its Coolidge, Arizona manufacturing facility is expected to be complete by April, months ahead of the original schedule. "Over the past several months, the Nikola team has been working to ensure the battery production transition plan was seamless and on schedule," said Michael Lohscheller, Nikola Corporation President and CEO. "We are pleased with the speed in which the plan has occurred and are grateful for the Cypress team's contribution." A battery engineering presence is expected to remain in California at a separate facility to focus on the development of Nikola's next generation battery management system software and modules.

16:29 EDT Lifecore initiates strategic review of alternatives - Lifecore announced that the board of directors of the company intends to initiate a process to evaluate the company's potential strategic alternatives to maximize value for stockholders. As part of the process, the board intends to consider a full range of strategic alternatives, which could include a sale of the company, potential debt or equity financing transactions, or other possible strategic transactions. The company expects to commence its strategic process once the company has obtained a forbearance agreement from its lenders that would provide forbearance and waivers under the company's existing credit agreements necessary to facilitate the company's strategic review process.

16:26 EDT Sarepta falls 20% after disclosing FDA AdCom meeting to be held for SRP-9001

16:23 EDT Sun Life Financial and Goodpath clinic partner for long COVID-19 treatment - Sun Life U.S. is expanding its health-related services by partnering with Goodpath, a Boston-based digital clinic, to provide disability members with access to integrative, holistic treatment for back or neck musculoskeletal conditions, or long COVID-19. Musculoskeletal issues are a leading cause of short-term disability claims, while long COVID, a complex condition, is an ongoing concern. Offering Goodpath to members on disability is part of Sun Life's commitment to broadening access to health benefits and services that complement the member's health insurance and drive improved health outcomes. Goodpath offers fully personalized, integrative care delivered digitally to address chronic conditions by focusing on symptoms and contributing factors, including secondary mental health issues. The app-based program provides digital tools as well as a monthly box of over-the-counter medications, devices and other treatment items shipped directly to the member's home. Goodpath will be available in Q2. Sun Life members receiving short-term disability benefits for back or neck musculoskeletal issues, or long-term disability for long COVID will be eligible. The program is an extension of their Sun Life disability benefit.

16:19 EDT Purple Innovation delays 10-K filing - The company has determined that it is unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense because it requires additional time to complete its financial statement preparation and review process. The company uses a number of SaaS solutions in its financial reporting processes. These service organizations provide annual evaluations over the effectiveness of their control environment, some of which are still outstanding or require additional follow up before the company can finalize its assessment over internal controls. The company expects to file its Form 10-K on or before Friday, March 31, which is within the fifteen-calendar day extension provided by Rule 12b-25.

16:17 EDT Leap Therapeutics provides update on BeiGene option agreement for DKN-01 - Leap Therapeutics (LPTX) announced that BeiGene's (BGNE) option under the Exclusive Option and License Agreement between Leap and BeiGene granting rights in certain Asian territories to DKN-01, Leap's anti-DKK1 monoclonal antibody, has expired in accordance with the terms of the agreement. Leap and BeiGene will continue to collaborate on the ongoing Part C of the DisTinGuish trial, a randomized controlled trial of DKN-01 in combination with BeiGene's anti-PD-1 antibody, tislelizumab, and chemotherapy in first-line gastric cancer patients, as a clinical collaboration with BeiGene supplying tislelizumab. Enrollment in the 160-patient study is expected to be completed in late 2023.

16:15 EDT Nutanix discloses listing deficiency notice from Nasdaq - Nutanix "announced that, on March 15, 2023, the Company received a standard notification letter from Nasdaq stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended January 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission."

16:13 EDT Sarepta says advisory committee meeting to be held for SRP-9001 - Sarepta Therapeutics announced that at its late cycle meeting for the SRP-9001 biologics license application, the U.S. Food and Drug Administration's Office of Therapeutics has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date. SRP-9001 is Sarepta's investigational gene therapy for the treatment of Duchenne muscular dystrophy. "FDA's decision to hold a public advisory committee meeting on the SRP 9001 BLA is a change from the communicated position at the midcycle meeting. FDA leadership has noted publicly that FDA is interested in exploring the use of surrogate endpoints, biomarkers, and innovative approaches like accelerated approval to advance cell and gene therapies, particularly for rare, life-ending degenerative diseases. It is our understanding that as one of the first gene therapy BLAs founded on a surrogate endpoint, the advisory committee will primarily relate to the totality of evidence supporting the conclusion that the SRP 9001 dystrophin is reasonably likely to predict clinical benefit, the standard for accelerated approval," said Doug Ingram, president and chief executive officer, Sarepta. "While we are disappointed that we must communicate a change in decision after our prior statement on the topic, we are not disappointed with the decision to hold an advisory committee. We had been preparing for an advisory committee meeting from the filing of the BLA in the fall of 2022. We will be well prepared, and look forward to presenting the wealth of evidence supporting the transformative potential of SRP-9001. We would like to thank CBER for moving expeditiously to schedule the advisory committee in advance of our May 29, 2023, regulatory action date, once the change in decision was made."

16:11 EDT Purple Innovation: Coliseum rejects committee's recent settlement proposal - The Special Committee of the Board of Directors of Purple Innovation announced that Coliseum Capital Management has rejected the Special Committee's most recent settlement proposal put forth on March 9. Coliseum owns approximately 44.7% of Purple, with the remaining shares owned by public market investors. "In response to Coliseum's multiple attempts to take over the Company without the payment of an adequate control premium, the Special Committee has been seeking a resolution that serves the best interests of all shareholders. We would like to ensure that the Public Shareholders, who own approximately 55% of Purple, continue to have influence over the Company and a voice in its governance," said Dawn Zier, Chair of the Special Committee of the Purple Board of Directors. "Unfortunately, Coliseum has rejected our proposal, which provided that Coliseum-nominated directors would fill three of the six non-management director seats on the Purple Board, giving them influence over the Board in proportion to their ownership stake in the Company. We will continue to work towards reaching a solution that treats all parties - including Coliseum - fairly."

16:07 EDT FedEx jumps about 8% to $219.42 after Q3 earnings beat, guidance raise

16:07 EDT FedEx says Q3 results impacted by 'continued demand weakness' - The company states: "Third quarter results were negatively affected by continued demand weakness, particularly at FedEx Express. In addition, operating income was negatively affected by the effects of global inflation, partially offset by U.S. domestic yield improvement and cost-reduction actions. FedEx Ground operating results improved, primarily due to an 11% increase in revenue per package and cost-reduction actions. These factors were partially offset by lower package volume, higher infrastructure costs and increased other operating expenses. FedEx Freight operating results improved, driven by an 11% increase in revenue per shipment and a gain on the sale of a facility, partially offset by decreased shipments. FedEx Express operating results declined due to lower global volumes, partially offset by a 3% increase in revenue per package. FedEx Express continues to implement volume-related and structural cost-reduction actions to mitigate the negative effect of ongoing demand weakness."

16:01 EDT FVCBankcorp extends buyback, may repurchase up to 1.3M shares of common stock - FVCBankcorp "announced that its Board of Directors has extended its share repurchase program that was initiated in 2020. Under the repurchase program, the Company may repurchase up to 1,300,000 shares of its common stock, or approximately 8% of its outstanding shares of common stock at December 31, 2022, post stock split effective January 31, 2023. The repurchase program will expire on March 31, 2024, subject to earlier termination of the program by the Board of Directors. Under the expiring program, the Company repurchased approximately 138,000 shares of its common stock at an average price of $14.16."

15:50 EDT Fed, Treasury say banks' deposits in First Republic show system's 'resilience' - The following statement was released by Secretary of the Treasury Janet Yellen, Federal Reserve Board Chair Jerome Powell, FDIC Chairman Martin Gruenberg, and Acting Comptroller of the Currency Michael Hsu: "Today, 11 banks announced $30 billion in deposits into First Republic Bank. This show of support by a group of large banks is most welcome, and demonstrates the resilience of the banking system."

15:25 EDT Group of banks confirm plan to make deposits totaling $30B in First Republic - Bank of America (BAC), Citigroup (C), JPMorgan Chase (JPM) and Wells Fargo (WFC) announced they are each making a $5B uninsured deposit into First Republic Bank (FRC). Goldman Sachs (GS) and Morgan Stanley (MS) are each making an uninsured deposit of $2.5B, and BNY Mellon (BK), PNC Bank (PNC), State Street (STT), Truist (TFC) and U.S. Bank (USB) are each making an uninsured deposit of $1B, for a total deposit from the eleven banks of $30B. "This action by America's largest banks reflects their confidence in First Republic and in banks of all sizes, and it demonstrates their overall commitment to helping banks serve their customers and communities. Regional, midsize and small banks are critical to the health and functioning of our financial system. Following the receiverships of Silicon Valley Bank and Signature Bank, there were outflows of uninsured deposits at a small number of banks. America's financial system is among the best in the world, and America's banks - large, midsize and community banks - do an extraordinary job serving the banking needs of their unique customers and communities. The banking system has strong credit, plenty of liquidity, strong capital and strong profitability. Recent events did nothing to change this. The actions of America's largest banks reflect their confidence in the country's banking system. Together, we are deploying our financial strength and liquidity into the larger system, where it is needed the most. Smaller- and medium-sized banks support their local customers and businesses, create millions of jobs and help uplift communities. America's larger banks stand united with all banks to support our economy and all of those around us," the group stated in a joint release.

15:19 EDT FDA advisory committee votes in support of safety and effectiveness of Paxlovid - Pfizer announced that the U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee, or AMDAC, voted 16 to 1 that available data support the safety and effectiveness of Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness. The AMDAC's vote, while not binding, will be considered by the FDA when making its decision regarding the potential approval of Paxlovid, the company noted. "We believe it is critical for adults who are at high risk of progression to severe COVID-19 to have access to safe and effective treatment options, like Paxlovid, to help prevent avoidable hospitalizations and deaths. We are encouraged by the AMDAC's positive vote today. The outcome is well supported by the strong safety and efficacy data seen both in our clinical trials and in a growing base of real-world evidence, showing that Paxlovid helps to reduce the risk of hospitalization or death for high-risk adult patients regardless of vaccination status," said James Rusnak, Senior Vice President and Chief Development Officer, Internal Medicine, Anti-infectives and Hospital, Pfizer.

14:00 EDT YouTube TV raises monthly price to $72.99 from $64.99 - Alphabet's YouTube TV said via Twitter, "An update for our members. As content costs have risen and we continue to invest in our quality of service, we'll be adjusting our monthly cost, after 3 years, from $64.99/mo to $72.99/mo, in order to bring you the best possible TV service. New members will see this new price today, while existing members will see this pricing change beginning 4/18. Additionally, we are lowering the price of our 4K Plus add-on from $19.99/mo to $9.99/mo. We are committed to offering a premium way for you to stream TV, but understand this new price may not work for you. We do hope YouTube TV continues to be your service of choice, but we want to give you the flexibility to cancel at any time."

13:55 EDT Volkswagen unveils all-electric ID. 2all concept car - Volkswagen yesterday unveiled the ID. 2all concept car, an all-electric VW vehicle costing less than EUR 25,000. The vehicle comes with front-wheel drive, range of up to 450 km, technological features such as Travel Assist, IQ.LIGHT or Electric Vehicle Route Planner and a new Volkswagen design language. The production version will be based on the MEB Entry platform and is one of ten new electric models that Volkswagen will launch by 2026. Thomas Schaefer, CEO of Volkswagen Passenger Cars: "We are transforming the company rapidly and fundamentally - with the clear objective of making Volkswagen a genuine Love Brand. The ID. 2all shows where we want to take the brand. We want to be close to the customer and offer top technology in combination with fantastic design. We are implementing the transformation at pace to bring electric mobility to the masses." Volkswagen will present the production version of the ID. 2all for the European market in 2025. The goal is a starting price of less than 25,000 euros. Reference Link

13:06 EDT Genelux Corp trading resumes

13:03 EDT First Republic turns positive, shares up 10% after reports of bank deposits

13:01 EDT Genelux Corp trading halted, volatility trading pause

12:10 EDT CEO of Amazon's Twitch announces resignation - Emmett Shear, the CEO of Amazon's Twitch, announced his resignation in a blog post. Shear said, "With my first child just born, I've been reflecting on my future with Twitch. Twitch often feels to me like a child I've been raising as well. And while I will always want to be there if Twitch needs me, at 16 years old it feels to me Twitch is ready to move out of the house and venture alone. So it is with great poignancy that I share my decision to resign from Twitch as CEO. I want to be fully there for my son as he enters this world and I feel ready for this change to tackle new challenges. I will continue to work at Twitch in an advisory role." Reference Link

12:00 EDT TEN, Ltd. falls -13.2% - TEN, Ltd. is down -13.2%, or -$2.88 to $18.92.

12:00 EDT First Republic falls -25.8% - First Republic is down -25.8%, or -$8.03 to $23.13.

12:00 EDT PagerDuty rises 17.4% - PagerDuty is up 17.4%, or $4.84 to $32.68.

11:29 EDT Fisker confirms banking relationship with JPMorgan Chase NA - Fisker (FSR) confirms its global banking and treasury management relationship with JPMorgan Chase NA (JPM). "Amid turmoil in the banking sector, Fisker's relationship with JPMorgan Chase provides us with strategic financial strength as we launch our first vehicle, the Fisker Ocean," said Chairman and CEO Henrik Fisker. He added that Fisker has no relationship with Silicon Valley Bank (SIVB), the startup-focused lender that the FDIC recently placed in receivership.

11:03 EDT Microsoft says 365 Copilot brings 'next-generation AI' to workplace productivity - Microsoft Corp. announced it is "bringing the power of next-generation AI to its workplace productivity tools" with "Microsoft 365 Copilot." Microsoft said: "Currently in testing with select commercial customers, Copilot combines the power of large language models with business data and the Microsoft 365 apps, to unleash creativity, unlock productivity and uplevel skills... Microsoft 365 Copilot isn't just a better way of doing the same things. It's an entirely new way of working... With Copilot, the customer is always in control. Customers decide what to keep, modify or discard. With these new tools, people can be more creative in Word, more analytical in Excel, more expressive in PowerPoint, more productive in Outlook and more collaborative in Teams." Jared Spataro, corporate vice president, Modern Work and Business Applications, Microsoft, added: "Copilot combines the power of large language models with your data and apps to turn your words into the most powerful productivity tool on the planet. By grounding in your business content and context, Copilot delivers results that are relevant and actionable. It's enterprise-ready, built on Microsoft's comprehensive approach to security, compliance, privacy and responsible AI. Copilot marks a new era of computing that will fundamentally transform the way we work."

10:26 EDT Baidu says over 30,000 enterprise users apply for ERNIE access after unveiling - Baidu announced that it introduced ERNIE Bot, a new-generation large language model and generative AI product. "ERNIE Bot excels in a range of areas, including understanding Chinese language and culture, generating literary and business writing, performing complex mathematical calculations, and producing multi-modal content. The AI product can comprehend human intentions and deliver accurate, logical, and fluent responses approaching human level. Starting March 16, 2023, ERNIE Bot will be open to an initial group of users with invitation codes and will soon be made available to more users. Baidu is also offering access to the ERNIE Bot API via Baidu AI Cloud, allowing enterprise clients to apply for and harness the platform's advanced language capabilities. Since February, over 650 enterprises have joined the ecosystem of ERNIE Bot. Large language models and generative AI represent a new technological paradigm, presenting an opportunity that no global enterprise can afford to miss. ERNIE Bot is positioned as a foundational AI empowering platform, designed to facilitate intelligent transformations across various industries such as finance, energy, media, and public affairs," the company stated. "In the first two hours following the press conference, more than 30,000 enterprise users have applied for access to the API of ERNIE Bot Enterprise Edition," the company said. Robin Li, Baidu Co-founder, Chairman and CEO said: "Baidu envisions a future where we join forces with all to drive the evolution of AI, empowering every individual with access to state-of-the-art productivity tools and ensuring that the benefits of these advancements are shared by all."

10:00 EDT Western Alliance falls -12.6% - Western Alliance is down -12.6%, or -$4.08 to $28.27.

10:00 EDT First Republic falls -29.4% - First Republic is down -29.4%, or -$9.15 to $22.01.

10:00 EDT PagerDuty rises 13.3% - PagerDuty is up 13.3%, or $3.70 to $31.54.

09:50 EDT Clene appoints Benjamin Greenberg as head of medical - Clene announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical. Dr. Greenberg joins Clene alongside his current role as professor of neurology and Vice Chair of Clinical and Translational Research in the Department of Neurology at UT Southwestern Medical Center in Dallas, TX. His clinical and research expertise spans many areas of neurology including the diagnosis and treatment of MS and other rare neurological disorders.

09:49 EDT Jorge Brito takes office as chairman of Banco Macro - Banco Macro S.A. announced that Jorge Brito took office as Chairman of the entity, replacing Delfin Jorge Ezequiel Carballo, who decided to anticipate the end of his term of office. Brito was acting as Vice Chairman of the Board of Banco Macro since November 30th 2020. In a letter addressed to the members of the Board, Ezequiel Carballo explained that he decided to leave because "the Bank is currently in an increasingly good situation as shown by its solvency, liquidity and other indicators usually used by analysts and investors in order to determine the sustainability of a financial entity. Also because I feel proud of the professional capacity of my colleagues in the Board of Directors, as well as of that of those who compose the entity's Top Management; so I have no doubt of their capacity to lead the Bank's destinies with the same efficiency as that with which they have been managed up to date."

09:47 EDT Burford Capital falls -20.1% - Burford Capital is down -20.1%, or -$1.54 to $6.13.

09:47 EDT Designer Brands rises 7.9% - Designer Brands is up 7.9%, or 65c to $8.93.

09:47 EDT UiPath rises 19.1% - UiPath is up 19.1%, or $2.80 to $17.44.

09:44 EDT First Republic trading resumes

09:39 EDT Norwood Financial trading resumes

09:36 EDT Western Alliance trading halted, volatility trading pause

09:33 EDT Pfizer recalls Nurtec ODT on packaging issues, risk of poisoning - Pfizer is recalling about 4.2M units of Nurtec ODT prescription drugs due to failure to meet child resistant packaging requirement; risk of poisoning. This recall involves prescription drugs Nurtec ODT 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets. The tablets are in a non-child resistant blister card packaged in a carton that includes the name of the product, dosage strength, NDC number and expiration date. Reference Link

09:27 EDT Hestia Capital believes Pitney Bowes value can be unlocked with new leadership - Hestia Capital Management is a top stockholder of Pitney Bowes, with an 8.4% stake in the Company. "We have invested a significant amount of capital, including the majority of our founder's personal net worth, in Pitney Bowes because we believe the Company's significant value can be unlocked with new leadership that is willing to pursue a more prudent strategy. As a fellow stockholder, our interests are squarely aligned with yours, unlike the executives and directors at Pitney Bowes who are handsomely paid regardless of their objectively poor performance. Despite the tremendous quality of Pitney Bowes' businesses, the Company's share price is down more than 50% and its credit rating has been downgraded six times during Chief Executive Officer Marc Lautenbach's more than 10-year tenure. We believe this long-term value destruction is wholly attributable to leadership's misguided strategy and poor execution, which the entire Board of Directors continues to fully support. With free cash flow plummeting almost 90% during Mr. Lautenbach's tenure to less than $100 million in 2022, it is imperative that the Company immediately change course to address its $1.7 billion in debt coming due in the next several years. In light of these factors, we are asking you to vote on the WHITE proxy card to elect all five of our highly qualified, independent director candidates to the Company's nine-member Board at the2023 Annual Meeting of Stockholders," said the company.

09:21 EDT System1 delays Q4 and yearly earnings report to review accounting - System1 announced that the Company is postponing its scheduled earnings release and conference call for the fourth quarter and full-year ended December 31 previously scheduled for today. The Company requires additional time to complete its preparation and corresponding review process of its consolidated financial statements as of and for the year ended December 31. Additionally, the Company is reviewing its accounting for last year's business combination transactions, including completion of its purchase accounting for business combinations and to perform its annual goodwill impairment analysis. In order to accommodate this schedule, the Company today filed a timely Notification of Late Filing on Form 12b-25 with respect to the Company's Annual Report on Form 10-K for the fiscal year ended December 31. As of today's date, the Company does not expect any material changes to its previously reported revenue or cash expenses for fiscal year 2022 to result from such review. The Company will announce the schedule for its fourth quarter and full-year ended December 31 financial results and conference call in a future press release.

09:10 EDT EnWave signs research, development license agreement with DTI - EnWave announced that it has signed a Research and Development License with the Danish Technological Institute, DTI, a leading research and technology company. DTI will acquire a 10kW Radiant Energy Vacuum machine to conduct product and process development work with several of their customers. DTI is known for helping their client base convert the newest knowledge and technology into value. The License will allow DTI to produce limited quantities of commercial products for market testing and analysis. EnWave believes that DTI has the network and capabilities to highlight the value proposition of REV technology in several industries and looks forward to fruitful collaborative work.

09:09 EDT Mullen expects Class 1 EV deliveries to commercial customers before March end - Mullen Automotive releases a statement from its CEO David Michery addressing recent investor inquires. The company said, "The Company addresses certain investor inquires as follows: Mullen anticipates making Class 1 EV deliveries to various commercial customers before the end of March 2023 in connection with the customer orders referenced below...On Dec. 14, 2022, Mullen announced a purchase order from Randy Marion Isuzu, LLC, a member of the Randy Marion Automotive Group, for 6,000 Class 1 EV Cargo Vans. This transaction is valued at approximately $200M...As of Feb. 28, 2023, Mullen has $87,400,009 of cash and cash equivalents, including restricted cash, and Mullen expects to receive an additional $110M from firm commitments by June 1, 2023. The Company believes the combination of cash on hand and expected firm cash commitments provides it enough capital to execute on its business plan over the next 12 months." "I believe we have all the pieces in place between our product, factories and strategic expertise to execute on our plans to deliver our Class 1 and Class 3 vehicles this year," said David Michery, CEO. "Furthermore, we continue to invest and move at a fast clip with the Mullen FIVE program, which will soon be approaching vehicle engineering freeze, allowing us to move into the next phase of the crossover program."

09:08 EDT Agora announces growth number of active users in 2022 - Agora has announced impressive growth in the number of active customers in 2022. The company's customer base increased by nearly 15%, adding 400 new customers to total 3,000 for the year. The surge in customer interest highlights the growing demand for interactive, two-way digital video and audio experiences. "We look forward to empowering more RTE start-ups in the region across the metaverse, social radio, education and entertainment industries, and supporting their ability to leverage new and exciting technologies that connect people in a more natural and meaningful way," said Tony Zhao, CEO & co-founder of Agora. In an era where people crave more engaging and interactive experiences, interactive real-time video and audio functionality are becoming essential in apps.

09:07 EDT Gevo enters joint development agreement with SIRE - Gevo announced that it has entered into a joint development agreement with Southwest Iowa Renewable Energy, SIRE, to measure, report and verify carbon intensity, CI, through the entire value chain, inclusive of climate-smart agriculture practices to lower the carbon footprint of SIRE's product portfolio. Utilizing the Verity Tracking platform under Gevo's newly created Verity Carbon Solutions business, this joint development agreement will focus on implementing tracking technology and developing the market for carbon inset credits that will help farmers and biofuel producers quantify the CI reductions for their products. This initiative plans to track reductions of CI to produce fuels and nutritional products through the use of "climate smart" agricultural practices, improvements in energy efficiency and potential use of defossilization of the input energy. "We are excited about our partnership with SIRE to track carbon intensity reductions through the entire value chain, creating high quality carbon insets. Unlike carbon offsets where the carbon reduction value is transferred to a value chain that may not be related, the carbon inset approach here allows carbon intensity reduction to be quantified throughout the value chain from the bushel to the gallon to drive continuous improvement," said Dr. Paul Bloom, Gevo's Chief Carbon & Innovation Officer. "For end customers who want to reduce their carbon footprint within the value chains in which they participate, this effort aims to provide measurable improvement and trust in verification of those efforts."

09:06 EDT Del Taco, Samuel Adams Boston Lager enter collaboration - Del Taco (JACK) has announced yet another example of its Del Taco Better Mex brand promise through a collaboration with The Boston Beer Company (SAM). The two brands have come together to offer award-winning Samuel Adams Boston Lager in Del Taco's fish taco beer batter recipe because better beer makes better fish tacos. Each taco features a wild-caught Alaska Pollock fillet coated in beer batter and topped with crunchy shredded cabbage and house-made pico de gallo served with a fresh-cut lime wedge.

09:05 EDT Fox Corp. announces 'Fox Future' Studio Lot Project - Fox Corporation has announced the creation of the Fox Future Studio Lot Project, which seeks to build the studio of the future amid the continued evolution of Century City. Born out of the Fox studio backlot, Century City was designed in 1957 to be the intersection of creativity, business, and entertainment production in Los Angeles, and Fox Future expands on that legacy. Given the rapid growth in entertainment production volume over the last decade and the company's long-term strategy, Fox has thoughtfully planned and prepared a forward looking and flexible investment to secure the future of this economically important and iconic studio property and ensure that Los Angeles remains the capital of the global entertainment industry. Fox Future is expected to be a major economic driver for the City of Los Angeles, responsible for an expected $1.5b in economic impact throughout Los Angeles County and will generate approximately $9M annually in tax dollars that can be used to fund public services such as schools, libraries and emergency response services, underscoring Fox's commitment to the community.

09:03 EDT Planet Fitness signs technology agreement extension with ABC Fitness Solutions - Planet Fitness has reached a new four-year agreement with ABC Fitness Solutions, a provider of technology and related services for the fitness industry. The Planet Fitness and ABC relationship began in 2014. This agreement will extend this partnership through 2027 and follows a comprehensive, year-long independent review conducted by Planet Fitness based on the company's current and future technology needs. Planet Fitness will upgrade to ABC's IGNITE club management solution across its US and Canada club locations to streamline its club technology operations.

09:02 EDT Centerspace sells nine communities in Minnesota, Nebraska for $144.3M - Centerspace announced the sale of nine communities located in Minnesota and Nebraska for an aggregate sales price of $144.3M. The sale included four communities in the St. Cloud market comprising 692 homes, two communities in the Omaha-Lincoln market comprising 498 homes, and three communities in the Minneapolis-St. Paul market comprising 377 homes. Proceeds from the sale will be used to pay down outstanding debt, thus reducing leverage and increasing the weighted average maturity of the company's debt obligations.

09:01 EDT Nvidia expands game roster, new developer plug-ins for NVIDIA DLSS 3 - NVIDIA announced an expanded game roster and new developer plug-ins for NVIDIA DLSS 3. The latest version of NVIDIA's AI-powered Deep Learning Super Sampling technology is now supported in an assortment of blockbuster games and franchises, and being integrated into Unreal Engine, one of the world's most popular game engines. The company is also publicly releasing the DLSS Frame Generation plug-in to further ease developer adoption of the technology.

08:54 EDT ReOrbit teams with SatixFy to develop processor for Gluon platform - ReOrbit and SatixFy Communications announced today a purchase deal of a communication subsystem for ReOrbit's Gluon platform. Gluon is a highly flexible software-defined satellite platform, capable of accommodating several types of payloads, from Earth Observation to Relay laser communications services. This platform will utilise state-of-the-art SatixFy radios to accommodate the need for high data rate links to enable communication between the ReOrbit Satellites and the ground segment. SatixFy's regenerative On-Board-Processor is the first of its kind re-using the Gen1 based on Sx3099 DVB-S2X SDR ASIC that was delivered in 2022 and will fly in the second quarter of 2023. This regenerative processor is re-configurable and built on modular and scalable solutions for Earth Observation or Telecommunication missions. "Collaboration is key to spearheading the digital transformation in the industry, and we're thrilled to foster it together with the SatixFy team to bring our flexible satellites to market. ReOrbit will continue to push the envelope and ensure we provide global critical services to cater to the time-to-market need of today's customers," says Sethu Saveda Suvanam, Founder & CEO of ReOrbit. "SatixFy's Satellite payload solutions offer low SWaP, modular, production-ready designs, software-reconfigurable capabilities, and operations. SatixFy's payloads solutions include the use of innovative, in-house-developed radiation hardened ASICs, which reduces the cost, complexity and risk of the final product," added Charlie Bloomfield, CEO of SatixFy Space Systems.

08:49 EDT Carahsoft to be Verint's Public Sector Distributor for engagement solutions - Verint announced its partnership with Carahsoft Technology. Under the agreement Carahsoft will serve as Verint's Public Sector Distributor, making the company's citizen engagement solutions available to the public sector through Carahsoft's reseller partners, NASA Solutions for Enterprise-Wide Procurement, SEWP, V and Information Technology Enterprise Solutions - Software 2, ITES-SW2, contracts. "Government agencies are immersed in a worldwide trend to improve their digital IQ and citizen engagement as reliance on government websites and content continues to expand. Consequently, leading global brands are meeting consumers where they want, when they want, and citizens expect this same level of service from government agencies," says Verint's John Bourne, senior vice president, global channels and alliances. "Verint's partnership with Carahsoft will help the public sector meet these challenges by extending the reach of our customer engagement solutions through Carahsoft's extensive reseller network." There are a number of government initiatives in place today that are driving the need for improved digital services and making citizen engagement a top priority. These include President Biden's Executive Order #14058 which focuses on transforming federal customer experience and service delivery to rebuild trust in government; and the Federal Risk and Authorization Management Program that simplifies security for the digital age by providing a standardized approach to security for the cloud. Verint solutions are FedRAMP Moderate/IL4 authorized, which comes on the heels of more than 20 years helping hundreds of agencies and departments around the world measure and improve citizen satisfaction.

08:47 EDT AIM ImmunoTech announces presentation on Ampligen in Ebola virus disease - AIM ImmunoTech announced a late-breaking presentation at the 36th International Conference on Antiviral Research detailing Ampligen's mechanism of action in the treatment of Ebola virus disease. The presentation was given by Angela Corona, PhD, Department of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy, and one of the published authors of a recent manuscript titled "Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action." Ebola virus is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of EVD in Central Africa capable of reaching epidemic status. Highlights of the recently published Ampligen data that was presented include: As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection. Ampligen appears to inactivate the EBOV lethal factor, which is believed to be responsible, in part, for the high mortality rate observed in humans, by acting as a "competitive decoy." VP35 is understood to sequester the dsRNA produced by EBOV during its replication, which inhibits the normal innate immune responses to viral infection. Ampligen protected mice from a lethal challenge by mouse adapted EBOV-Zaire and its associated weight loss. The 6 mg/kg doses, frequently used in AIM's clinical trials, used in mouse model is easily achievable and well tolerated in humans. Overall, the data suggest Ampligen's potential as a viable candidate to protect against exposure to EBOV.

08:42 EDT Blue Apron continues to work with DoorDash via DashMart storefront, says CEO

08:42 EDT Blue Apron sees Q1 customer count up sequentially, in line with seasonality - Expects decline y/y in Q1 customer count.

08:40 EDT Aclara Resources secures 100% recycled water source for Penco Module - Aclara Resources secured a recycled water source, which fulfills the full water requirement of the Penco Module. This represents a major milestone in improving the environmental attributes of the Project and strengthens the Company's position in preparation of filing its enhanced Environmental Impact Assessment application in the second quarter of 2023. The Company has confirmed that its decision to obtain a 100% recycled water source was made as a result of its ongoing dialogue with the community to further improve the sustainability measures of the Project. The recycled water will be provided by Essbio, the water utility company of Concepcion, which collects water from the city and treats it prior to discharge into the environment. This solution is the result of collaborative efforts between Aclara and Essbio to preserve the area's hydric resources and to develop the first fully recycled water supply project in the Biobio region.

08:37 EDT AMC Networks terminates cash tender offers for senior notes - AMC Networks has terminated its previously announced cash tender offers, the terms and conditions of which are described in an Offer to Purchase, dated February 17, 2023, to purchase up to $800,000,000 aggregate principal amount of its outstanding 5.00% Senior Notes due 2024 and 4.75% Senior Notes due 2025 as a result of the Financing Condition not having been satisfied. As a result of the termination of the Offers, no Notes will be purchased in the Offers and all Notes validly tendered will be promptly returned to tendering holders. No consideration will be paid in the Offers for any of the tendered Notes.

08:37 EDT Blue Apron: Working towards stabilizing balance sheet - Comments taken from Q4 earnings conference call.

08:36 EDT Berkshire Hathaway buys 7.9M shares of Occidental Petroleum for $466.68M - Berkshire Hathaway (BRK.A) purchased more Occidental (OXY) shares, increasing its stake in the oil company to about 23.1%, according to a regulatory filing on Wednesday. Berkshire paid about $466.68M for 7.9M Occidental shares between March 13 and March 15, according to the filing. Berkshire Hathaway previously said it resumed its purchases of Occidental shares after a hiatus.

08:34 EDT Shattuck Labs presents preclinical data at 2023 AACR meeting - Shattuck Labs announced preclinical data at the 2023 American Association for Cancer Research, AACR, Annual Meeting in Orlando, Florida, from the company's GADLEN platform. "We are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human Vgamma9Vdelta2 T cells to serially kill greater than 99% of human B cells in a humanized mouse model," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "These data led to the first study of a GADLEN compound in non-human primates, where once again treatment with a CD20-targeted GADLEN directed low frequencies of endogenous Vgamma9Vdelta2 T cells to eliminate CD20 positive B cells with a rapid kinetic. Importantly, the GADLEN compound was well tolerated in non-human primates up to the highest administered dose of 25 mg/kg, without evidence of cytokine release syndrome or other toxicities, potentially providing differentiation from CD3-directed T cell engagers. These data underlie our enthusiasm to advance a GADLEN product candidate into the clinic designed for the treatment of antibody-mediated autoimmune diseases." Details of the presentations are as follows: Abstract title: Rapid Serial Killing of Target Cells by Vgamma9Vdelta2 T Cells in Cynomolgus Macaques and Humanized Mice Treated with a CD20-Directed Heterodimeric Butyrophilin 2A1/3A1 Fusion Protein

08:33 EDT Arrival announces board member Hwang stepping down from position - Arrival has announced that Dr. Yunseong Hwang has stepped down from the Arrival Board of Directors, effective immediately. Dr. Hwang has served on Arrival's Board of Directors since July 2021 and was a member of the Nominating and Corporate Governance Committee.

08:32 EDT Snail announces content updates for ARK: Dinosaur Discovery - Snail announced the first major content update for ARK: Dinosaur Discovery. ARK: Dinosaur Discovery, currently exclusive to Nintendo Switch, is an educational adventure designed for younger players, allowing them to explore the ARK island without violence and learn about prehistoric creatures that inspired ARK: Survival Evolved. Players who purchase ARK: Ultimate Survivor Edition can download ARK: Dinosaur Discovery for free, and the game is also available for $9.99 on the Nintendo eShop. The major content update includes a full game map accessible from a player's bookshelf, teleport abilities to any previously discovered creature zones, a whistle feature to immediately spawn a tamed creature to a location, and improvements to all creature movement animations. Additionally, the game now has full language support for Japanese, Simplified Chinese, and Traditional Chinese.

08:31 EDT Clearmind Medicine submits IND application to FDA for CMND-100 - Clearmind Medicine announced it has submitted an Investigational New Drug, IND, application with the U.S. Food and Drug Administration, FDA, requesting approval to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from alcohol use disorder, AUD. Pending regulatory approval, the company plans to initiate the CMND-100 trial in Q2 2023. "From studies with MEAI, we believe it has potential to break the vicious drinking cycle at the point of the decision to drink more alcohol, by potentially innervating neural pathways that lead to sensible behavior," said Dr. Adi Zuloff-Shani, Clearmind's CEO. "Globally, AUD causes many billions of dollars in healthcare costs and millions of deaths each year. The IND submission to FDA, to initiate our clinical trial, is a milestone showing the huge commitment of the Clearmind team to finding a solution to this abusive disorder. We're thrilled to be a step closer to helping patients with severely unmet medical needs."

08:24 EDT Dirtt Environmental agrees to reimburse 22NW for expenses related to election - DIRTT Environmental Solutions entered into agreements with Aron English and 22NW Fund, where the Company acknowledges it is indebted to and will reimburse 22NW for the expenses incurred by 22NW in connection with the Company's contested director election at the annual and special meeting of shareholders held on April 26, 2022. The total expenses to be reimbursed are $1,559,898. Subject to the receipt of shareholder approval, which is required under the rules of the Toronto Stock Exchange and the Nasdaq Capital Market, the Company has agreed to issue common shares as settlement of the debt. The issuance of the shares, priced at $0.40, will be put before the Company's shareholders for consideration and approval at the Company's upcoming 2023 annual and special meeting.

08:22 EDT Zoom Video, MLB announce partnership to enhance MLB games, fan viewship - Major League Baseball, MLB, and Zoom Video Communications announced a first-of-its-kind partnership for the league, aimed to enhance MLB games and the fan viewership experience. As the new Official Unified Communications Platform of MLB, Zoom Contact Center and the Zoom platform technology will power new elements of Major League games and broadcasts. Zoom Chief Marketing Officer, Janine Pelosi said: "MLB brings together tens of millions of passionate fans every season. Zoom's rapid pace of innovation and obsession with making human connection easier and better, is crucial to help MLB evolve its experience and deliver unprecedented transparency and access to its fans. With MLB leveraging Zoom Contact Center and Zoom's all-in-one collaboration platform, we are able to truly show the world how a historical brand can continue to innovate and unlock new possibilities."

08:21 EDT Osisko Mining announces definitive agreement with Miyuukaa - Osisko Mining announce that it has concluded the previously announced binding term sheet agreement and signed a definitive agreement with Miyuukaa, with respect to the construction of proposed transmission facilities and the transport of hydroelectric power to the Windfall Project, located in the Abitibi greenstone belt, Eeyou Istchee James Bay, Quebec. The power line from the Waswanipi substation to Windfall is located 100% on CFNW traditional lands covered by the James Bay Northern Quebec Agreement. Miyuukaa will finance, build, own and operate a 69 kV dedicated transmission line that will transport hydroelectricity to the Windfall project. As an end user, Osisko will pay service fees to Miyuukaa. The agreement outlines the general and financial terms of the agreement between Osisko and Miyuukaa, which is for the purpose of ensuring delivery of hydroelectricity over the life of the planned Windfall mill as required. Construction work commenced during the first quarter of 2023 and is projected to take 12 months to complete, with the hook-up date anticipated in Q1 2024. This agreement solidifies the collaborative approach between Osisko and the CFNW to sustainably develop energy infrastructure, which will create robust employment opportunities for members of the CFNW.

08:19 EDT In8bio to present preclinical data on novel gamma-delta CAR platform at AACR - IN8bio has announced that preclinical data for its gamma-delta CAR-T technology, INB-300, will be presented at the American Association for Cancer Research, AACR, Annual Meeting 2023. The event will be held in Orlando, Florida, from April 14-19. IN8bio's non-signaling CAR platform is based on the natural innate immune recognition of gamma-delta T cells. By using a CAR that lacks a CD3z signaling domain, IN8bio believes it has created a technology that enables these cells to differentiate between tumor and healthy tissue, even when both express the CAR-targeted antigen. IN8bio is not seeking to advance this construct into the clinic but the data to be presented includes a proof-of-concept study against the validated target of CD19. "We are thrilled to present promising preclinical data from our next-generation CAR platform, which shows the potential of INB-300 to differentiate between cancerous and healthy tissue," said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. "Our goal is to improve upon existing technologies with a targeted and potentially less toxic approach for patients who require more innovative therapies. We are encouraged by these results and look forward to further evaluating nsCAR programs in additional promising targets such as CD33 for acute myeloid leukemia."

08:18 EDT Keysight Technologies: Ron Nersesian to transition to non-executive chair May 1 - Keysight Technologies announced that Ron Nersesian, the company's Executive Chair of the Board of Directors, plans to transition to Non-Executive Chair as of May 1. Nersesian has served as Keysight's Executive Chairman since November 2019 and transitioned the role of Keysight President and Chief Executive Officer to Satish Dhanasekaran in May 2022. Nersesian has spent more than 30 years with the company and its predecessors. "Serving as Keysight's President and CEO from 2013 to 2022 and Executive Chair for the last year, has been one of my greatest honors and achievements," said Ron Nersesian, Keysight's Executive Chair. "Looking ahead, I strongly believe Keysight has exciting prospects to extend its track record of value creation for customers, shareholders, and employees."

08:15 EDT ABB to invest $20M to expand robotics factory in the U.S. - ABB announced construction starting on the expansion of its existing North American robotics headquarters and manufacturing facility in Auburn Hills, Michigan. The project is expected to be completed in November 2023 and represents an investment of $20M. The expansion will create 72 highly skilled new jobs in the area and is supported by a $450,000 Michigan Business Development Program performance-based grant.

08:14 EDT Allstate sees February catastrophe losses $211M, or $167M after-tax - In a regulatory filing, Allstate announced estimated catastrophe losses for the month of February of $211M or $167M, after-tax. Catastrophe losses for February events were estimated at $241M, related to nine events primarily from wind and rain that were geographically widespread, partially offset by favorable reserve re-estimates for prior events. Catastrophe losses for January and February totaled $518M, pre-tax. "Allstate continued to implement significant auto insurance rate actions in response to inflationary increases to loss costs. During the month of February, the Allstate brand implemented auto rate increases of 7.6% across 10 locations, resulting in total brand premium impact of 0.5% which are expected to raise annualized written premiums by approximately $127 million," said Jess Merten, CFO of The Allstate Corporation. Our implemented auto rate exhibit has been posted on allstateinvestors.com.

08:12 EDT AcuityAds confirms all monies recovered from SVB - AcuityAds (ATY) provided an update on its previously disclosed cash deposits with Silicon Valley Bank (SIVB), SVB. The Company is pleased to report that all monies mentioned in its press release dated March 10, 2023, have been recovered from SVB and are currently on account at a Canadian Schedule I bank. "I want to thank our team for working tirelessly around the clock this weekend to ensure we had no operational interruptions with our clients, vendors or employees," said Tal Hayek, Co-Founder and Chief Executive Officer of AcuityAds. "After reporting strong fourth quarter 2022 results on the back of tremendous illumin momentum, we can now turn our attention back to growing our business and continuing to increase our market share."

08:07 EDT NuZee announces private label agreement with Wakefern Food Corp. - NuZee announces its first private label agreement with Wakefern Food Corp., the largest retailer-owned cooperative in the United States. Under ShopRite's private label brand Bowl & Basket, NuZee packed and shipped three single serve coffee brew-bag items: Breakfast Blend, French Roast and Colombian. The Bowl & Basket single-serve coffees launched recently at ShopRite stores. The product will be available in approximately 250 ShopRite locations.

08:03 EDT Arlo Technologies exceeds 2M total paid subscribers - Arlo Technologies announced it has surpassed 2M total paid subscribers. "After adding 189,000 paid accounts in Q4 2022, Arlo continued to acquire new subscribers in Q1, reaching 2 million total subscribers and doubling our paid accounts in just five quarters," said Matt McRae, CEO of Arlo. "Additionally, new products like the Arlo Home Security System backed by Professional Monitoring and Arlo Safe will add to our pace of subscriber acquisition in 2023. This continued success illustrates the value we provide to customers as we help them stay protected both at home and on the go."

07:59 EDT Costamare announces up to $200M investment in Neptune Maritime Leasing - Costamare has agreed to become the leading investor in Neptune Maritime Leasing through the investment of an amount of up to $200 million. Neptune Leasing is a growth-oriented maritime leasing platform providing flexible financing solutions to shipowners, which was established in 2021 by seasoned financier Harris Antoniou, who will continue as CEO. Vassilis Mantzavinos, an experienced shipping banker, will be appointed, among others, as an additional Board member of Neptune Leasing on behalf of Costamare. The company said, "Costamare is pleased to be teaming up in this venture with Neptune Leasing's anchor investor, Latsco Family Office, the Family Office of Marianna J. Latsis' family, which is also increasing its investment in Neptune Leasing. Considering current asset values, the Company believes that the Neptune Leasing investment is a favourable employment of the Company's increased liquidity and is expected to provide healthy returns at acceptable risk levels. The new venture is synergetic to the existing ship owning platform and is expected to further enhance the strong relationships built over the last decades with shipowners and commercial lenders in the ship financing sector."

07:50 EDT BK Technologies board decides to suspend quarterly cash dividend - BK Technologies announces that its Board of Directors has elected to suspend the Company's quarterly cash dividend of $0.03 per common share until further notice. The Company took this action as it believes all of its available resources should be focused on delivering on the strong demand BK is experiencing with the BKR 5000, in preparation for the formal launch of the BKR 9000, and to support the continued launch of its first SaaS offering, InteropONE with new customers.

07:46 EDT NeoGenomics announces commercial availability of RaDaR assay - NeoGenomics announced the commercial availability of the RaDaR assay, a liquid biopsy test for molecular/minimal residual disease. MRD is the trace amounts of circulating tumor DNA that remain after surgery or other cancer treatment. The announcement comes after several recent publications demonstrating the clinical utility of the RaDaR test, particularly in the breast cancer space, with the CHiRP study published at ASCO 2022, and presentations of data for the TRACER and cTRAK-TN study cohorts at the most recent SABCS conference.

07:44 EDT Court rules Lenovo should pay $138.7M for license to InterDigital's patents - InterDigital (IDCC) announced that the UK's High Court handed down its judgment in the company's licensing dispute with Lenovo (LNVGY). The Court ruled that Lenovo should pay a total of $138.7M for a license to InterDigital's portfolio of 3G, 4G and 5G patents, and should pay in full for past sales dating back to 2007. The Court will decide in due course whether additional interest is due on the past payments.

07:42 EDT Draganfly increases production capacity with expanded production facility - Draganfly announces the expanding of its production capabilities to meet the rapidly growing demand for its drone technology by bringing its facility in Burnaby, B.C. online. Draganfly's has expanded its facility in Burnaby to enable the production and manufacturing of UAV systems and components, including those for the Draganfly Heavy Lift and Commander 3XL, increasing production capacity to meet demand based on client orders and for the company to serve its global customers. "We are thrilled to announce this expansion of our manufacturing capabilities," said Cameron Chell, President and CEO of Draganfly. "This facility reflects our ability to meet the ever-growing demand for Draganfly products and our commitment to better serve our customers by providing the highest quality drone products."

07:41 EDT Pyxis Oncology announces dosing of first subject in Phase 1 trial of PYX-201 - Pyxis Oncology announced dosing of the first subject in a Phase 1 trial of PYX-201. PYX-201 is a novel antibody-drug conjugate, ADC, product candidate licensed from Pfizer targeting extradomain-B, EDB, of fibronectin, a non-internalizing antigen, that is an integral component of the extracellular matrix in tumors. EDB fibronectin is overexpressed in many solid tumors and minimally expressed in most normal adult tissues. The Company anticipates preliminary data from this trial in early 2024. "PYX-201 has the potential to offer a new approach to targeting multiple tumor types via a multipronged mechanism of action that may benefit patients with solid tumors. We expect to see preliminary data from this study, including biomarker results and potential early signs of clinical activity, in early 2024," said Lara Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "I'm proud of the work done by the Pyxis Oncology team to initiate dosing in our first clinical trial. Dosing is a significant achievement and important milestone that marks the transition of Pyxis Oncology to a clinical-stage company."

07:37 EDT Becton Dickinson receives FDA clearance for BD Vaginal Panel - Becton Dickinson announced that it has received 510(k) clearance from the FDA for the BD Vaginal Panel on the BD COR System, a diagnostic test that directly detects the three most common infectious causes of vaginitis using BD's high-throughput molecular diagnostic platform for large laboratories.

07:36 EDT Destination XL board approves $15M stock repurchase program - On March 14, 2023, the Board of Directors authorized a new stock repurchase program, effective March 16, 2023, whereby we may repurchase up to $15.0 million of our common stock through open market and privately negotiated transactions. The timing and the amount of any repurchases of common stock will be determined based on the Company's evaluation of market conditions and other factors. The stock repurchase program will expire on March 16, 2024. The stock repurchase program may be suspended, terminated or modified at any time for any reason. We expect to finance the repurchases from operating funds and/or periodic borrowings on our credit facility. Any repurchased common stock will be held as treasury stock.

07:34 EDT Aldeyra completes enrollment in trial of ADX-2191 in retinitis pigmentos - Aldeyra Therapeutics announced the completion of enrollment in the Phase 2 clinical trial of ADX-2191 , an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration -approved treatment. The open-label, single-center Phase 2 clinical trial enrolled a total of eight retinitis pigmentosa patients with rhodopsin gene mutations, including the P23H gene mutation. Patients receive either monthly or twice-monthly intravitreal doses of ADX-2191 for three months. The primary endpoint of the trial is safety. Secondary endpoints include change from baseline in visual acuity; retinal function, as assessed by foveal microperimetry, electroretinography, and dark adaptation; and retinal morphology, as assessed by optical coherence tomography. "Given the lack of FDA-approved therapies for retinitis pigmentosa, a sight-threatening group of diseases that affect more than one million patients worldwide, novel therapeutic approaches are in demand," stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. "Aldeyra is committed to working with patients and physicians to attempt to ameliorate the unrelenting burden of retinitis pigmentosa, and we look forward to reporting top-line results of the Phase 2 clinical trial in the first half of this year."

07:29 EDT Alterity Therapeutics enrolls first patient in U.S. in ATH434 Phase 2 trial - Alterity Therapeutics announced the first participant has been dosed in the U.S. in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA. The study will evaluate the effect of ATH434 treatment on neuroimaging and protein biomarkers to demonstrate target engagement, and clinical endpoints to demonstrate efficacy, in addition to assessments of safety and pharmacokinetics. The selected biomarkers, including brain iron and aggregating alpha-synuclein, are important contributors to MSA pathology and are therefore appropriate targets to demonstrate drug activity. Wearable sensors will also be employed to evaluate motor activities that are important to patients with MSA. The study is expected to enroll approximately 60 adults to receive one of two dose levels of ATH434 or placebo. Participants will receive treatment for 12 months which will provide an opportunity to detect changes in efficacy endpoints to optimize design of a definitive Phase 3 study.

07:24 EDT Acreage's floating shareholders approve approve arrangement with Canopy Growth - Acreage Holdings (ACRHF) announced that, at a special meeting of holders of Acreage's Class D subordinate voting shares held on March 15, 2023, the Floating Shareholders voted in favor of a special resolution authorizing and approving the arrangement under section 288 of the Business Corporations Act with Canopy Growth Corporation and Canopy USA, and matters related thereto. The Arrangement Resolution required approval by at least 66 2/3% of the votes cast at the Meeting by the Floating Shareholders. Additionally, pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, the Arrangement Resolution required approval by at least a majority of votes cast at the Meeting by the Floating Shareholders, excluding the Floating Shares held by any "interested party", any "related party" of an "interested party" or any "joint actor", all as more particularly described in Acreage's proxy statement and management information circular mailed to Floating Shareholders in connection with the Meeting. Acreage expects that the hearing date for the application for the final order of the Supreme Court of British Columbia will take place on or about March 20, 2023 in Vancouver, British Columbia. In accordance with the terms of the floating share arrangement agreement dated October 24, 2022, among the Company, Canopy and Canopy USA, Canopy has agreed, subject to the terms and conditions set forth therein, to exercise its option pursuant to the arrangement agreement between Canopy and Acreage dated April 18, 2019, as amended to acquire Acreage's outstanding Class E subordinate voting shares, representing approximately 70% of the total shares of Acreage as at the date hereof, at a fixed exchange ratio of 0.3048 of a common share of Canopy for each Fixed Share held, such exercise to occur no later than five business days following the satisfaction of all required conditions. Upon completion of: the acquisition of the Floating Shares pursuant to the Floating Share Arrangement; and the acquisition of the Fixed Shares pursuant to the arrangement under Section 288 of the BCBCA on the terms and conditions set out in the Existing Arrangement Agreement, Canopy USA will own 100% of the issued and outstanding shares in the capital of Acreage. Upon receipt of the Final Order and the satisfaction or waiver of all other conditions set out in the Floating Share Arrangement Agreement, which the parties continue to work towards, the parties will complete the Floating Share Arrangement.

07:21 EDT Red White & Bloom Brands appoints Edoardo Mattei as CFO - Red White & Bloom Brands confirms the appointment of Mr. Edoardo Mattei as its CFO, subject to final US state regulatory approval. As of December 1st, 2022, Eddie was contracted by the Company in a fractional role to assist with the orderly transition and timely restructuring of the Company's Finance, Information Technology, and Human Resources teams. Effective March 15, 2023, subject to the aforementioned regulatory approval, Eddie will assume the role of CFO and will also be appointed the Company's Corporate Secretary. Eddie will be based at the Company's headquarters in Toronto, Ontario. The Company further reports that it has issued 1,250,000 stock options to an officer of the Company. The stock options are exercisable to acquire up to 1,250,000 common shares of the Company at an exercise price of $0.10 for a period of ten years from issuance. The stock options vest quarterly over a period of two years commencing on the first anniversary date of the grant. The terms for the grant are in line with the parameters set out in the Company's existing Employee Stock Option Plan

07:19 EDT Bio-Path provides clinical, operational update - Bio-Path Holdings provides a clinical development and operational update. Important Near-Term Clinical Milestones: BP1001-A Phase 1/1b Clinical Trial in Solid Tumors; BP1002 Phase 1/1b Clinical Trial in Relapsed/Refractory AML; Prexigebersen Phase 2 Clinical Trial in AML. Clinical Program Overview: Bio-Path's clinical development program consists of one Phase 2 clinical trial and three Phase 1 or 1/1b clinical trials. Phase 2 Clinical Trial - Bio-Path's Phase 2 clinical trial is treating Acute Myeloid Leukemia patients. This trial is comprised of three separate cohorts of patients and treatments, each separately approvable by the FDA as a new drug treatment. The interim analysis of each cohort to assess the safety and efficacy of treatment combination therapy is expected to commence by cohort in the second quarter of 2023, with the potential to qualify for expedited regulatory status. Phase 1/1b Clinical Trial in BP1001-A in Advanced Solid Tumors - Phase 1/1b clinical trial of BP1001-A in patients with advanced or recurrent solid tumors, including ovarian and uterine, pancreatic and breast cancer. Completion of the first dose escalation cohort is expected in the coming months. Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML. Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients. Completion of the first dose escalation cohort is expected in the coming months. Phase 1 Clinical Trial in BP1002 in Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia. Phase 1 clinical trial for refractory/relapsed lymphoma and CLL. Completion of the current patient cohort is expected in 2023. Preclinical Work for BP1003. The Company continues to advance its drug candidate, BP1003, for the treatment of advanced solid tumors, including pancreatic cancer. BP1003 is an antisense RNAi nanoparticle targeting the STAT3 protein. Plans are to conduct a Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors. Manufacturing Supply: The COVID-19 pandemic created manufacturing interruptions over the last several years. The result of these factors led Bio-Path to double the Company's supply chain, increase capacity, quality and improve scheduling flexibility. These goals were achieved in 2022 and have resulted in increased drug candidate supply, quality and patient enrollment. Intellectual Property Protection: Bio-Path's patent portfolio is as follows: New composition and methods of use patent issued covers DNAbilize technology, solely owned by Bio-Path. Five patents issued in the United States; eight foreign patents issued; one additional foreign patent application allowed. Five applications pending in the United States along with 60+ applications pending in foreign jurisdictions

07:16 EDT GXO Logistics partners with SPANX to provide warehousing solutions - GXO Logistics announced that it is partnering with SPANX to provide warehousing solutions for the functional fashion brand at a new facility in Flowery Branch, Ga. As a brand founded on a mission to empower women, the company selected a logistics partner that shared its mission. "We're excited to partner with SPANX, a true creator and innovator in the fashion space," said Christy Hillier, Operations Senior Director who oversees GXO's Flowery Branch facility. "We're bringing our expertise in warehouse technology, including collaborative robots, to help SPANX improve its efficiency, quality and customer service. We're proud to support SPANX's mission to 'help women feel great about themselves and their potential.'" GXO's 445,000-square-foot dedicated site northeast of Atlanta employs nearly 200 people and uses 6 River Systems collaborative robots, or cobots, to improve efficiency and to enhance employees' safety and their overall work experience.

07:15 EDT Tonix Pharmaceuticals initiates enrollment in Phase 2 UPLIFT study - Tonix Pharmaceuticals announced that the first participant was enrolled in the Phase 2 'UPLIFT' study of TNX-601 ER1 for the treatment of major depressive disorder, MDD. The double-blind, placebo-controlled registrational-quality study has a target enrollment of 300 participants at approximately 30 sites across the U.S. Results from a planned interim analysis are expected to be released in the fourth quarter of 2023. "Despite the availability of several classes of MDD treatments in the U.S. that directly modulate neurotransmitters and their synaptic receptors, there remains an unmet need for novel approaches," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "In animal studies, TNX-601 ER has a unique mechanism of action that restores brain neuroplasticity by exerting biological effects on neurons and glial cells that increase arborization of dendrites in critical hippocampal circuits.2 In animal models, tianeptine also reverses stress-induced impairments in synaptic glutamate neurotransmission, and it restores hippocampal neurogenesis.2"

07:14 EDT Purple Biotech reports biomarker data from CM24 Phase 1 dose escalation study - Purple Biotech provided new results from exploratory analyses conducted as part of a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma, two patients with colorectal adenocarcinoma (CRC) and one patient with papillary thyroid cancer. The analyses conducted in eight evaluable PDAC patients demonstrate clinically meaningful and durable reductions in serum myeloperoxidase, a biomarker for NETs, following treatment with CM24 plus nivolumab, immediately and 15 days after the first administration. In addition, analyses of tumor samples derived from the evaluable PDAC patients suggest that patient survival may be positively associated with higher levels of CEACAM1+ tumor-infiltrating lymphocytes in the TME. These results, along with additional data from this clinical study, are part of the Company's effort aimed at identifying and evaluating the potential utility of a biomarker to optimize patient selection and treatment. "These encouraging biomarker results provide initial evidence of certain mechanistically relevant biomarkers and may enable us to implement a biomarker-driven strategy that could identify patients who will benefit from CM24," said Gil Efron, Chief Executive Officer, Purple Biotech. "We look forward to further data that may establish these findings in our ongoing randomized Phase 2 clinical study evaluating CM24 in combination with nivolumab and chemotherapy for treatment of PDAC."

07:11 EDT CGI Inc. enters global alliance partnership with NetApp - CGI (GIB) announced a new global alliance partnership with NetApp (NTAP) focused on helping organizations across industry sectors unlock the full potential of hybrid and multi-cloud environments to drive flexibility, efficiencies and cost savings in the management of their applications and use of their data. Through this new alliance, CGI and NetApp will provide clients with a single, consistent cloud environment, unified data services, and centralized management that supports full visibility of both on-premise and cloud-based systems and data.

07:04 EDT AC Immune sees 2023 cash burn CHF 65M - CHF 75M - AC Immune anticipates that its total cash burn will be in the range of CHF 65 to CHF 75 million for the full year 2023. The Company defines cash burn as operating expenditures adjusted to include capital expenditures and offset by significant non-cash items

06:56 EDT Dollar General raises quarterly dividend to 59c per share - Payable on or before April 25 to shareholders of record on April 11.

06:24 EDT Blue Apron not providing any forward looking guidance at this time - In line with the company's comments in 3Q22, Blue Apron is not providing any forward looking guidance at this time. The company remains focused on achieving adjusted EBITDA profitability, and stabilizing the overall balance sheet and liquidity position.

06:03 EDT Exxon Mobil launches $2B Beaumont refinery expansion - ExxonMobil announced the startup of its Beaumont refinery expansion project, which adds 250,000 barrels per day of capacity to the refining and petrochemical complex on the U.S. Gulf Coast. The added volume in Beaumont brings total processing capacity to more than 630,000 barrels per day. ExxonMobil has hired more than 50 full-time employees to help with the operation of the expanded refinery. ExxonMobil's integrated operations in Beaumont also include chemical, lubricants and polyethylene plants. ExxonMobil has approximately 2,100 employees in the Beaumont area and its operations account for approximately 1 in every 7 jobs in the region.

05:58 EDT Honda recalls 500,000 CR-Vs, Accords, Odysseys over seat belt problem - Honda is recalling nearly 500,000 vehicles in the US and Canada because the front seat belts may not latch properly. The recall covers models including the 2017 through 2020 CR-V, the 2018 and 2019 Accord, the 2018 through 2020 Odyssey and the 2019 Insight. Also included is the Acura RDX from the 2019 and 2020 model years. Honda says in documents posted Wednesday by US safety regulators that the surface coating on the channel for the buckle can deteriorate over time. Honda says it has no reports of injuries caused by the problem. Reference Link

05:14 EDT OKYO Pharma announces OK-101 trial listed on ClinicalTrials.gov public website - OKYO Pharma announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website. ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. OKYO is presently in the process of activating those clinical sites planned for the trial, and preparing the clinical trial drug product OK-101 for shipment to those sites involved in the double-blind, placebo-controlled trial, along with other activities needed for initiating the trial. OKYO is now anticipating the first-patient first-visit initiation of the trial in early Q2 and still looking to release top-line data from this trial in Q4.